Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMG-007 in Moderate-to-Severe Atopic Dermatitis
2023-505735-13-01Phase 2Completed
- Sponsor
- Inmagene Biopharmaceuticals
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, double-blind trial of IMG-007 in atopic dermatitis (AD) (2 arms), sponsored by Inmagene Biopharmaceuticals. Primary endpoint: Incidence of TEAEs. Started Mar 2024; status: completed.
02
Drugs
IMG-007
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2023-505735-13-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505735-13-01.